ClinicalTrials.gg
RecruitingNCT06584084Updated Sep 19, 2024

Technical and Clinical Validation of the WPM-SEMG Prototype

An interventional study of WPM-SEMG prototype in Neuron Disease, Motor, sponsored by Alain Kaelin. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Alain Kaelin · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Validation study designed to demonstrate the technical and clinical performance, and the safety of a new medical device in healthy volunteers and patients with myopathy or neuropathy. The medical device is the WPM-SEMG prototype designed for recording electrophysiological signals of muscles.

Read the detailed description

The study consists of two parts:

  • the first part concerns the technical validation of the prototype. It will enrol 10 healthy volunteers (Technical Validation Group).
  • the second part concerns the clinical validation of the prototype in comparison with the gold standard, that is the needle-EMG. It will enrol 50 healthy volunteers (Clinical Validation Group), including also the 10 subjects of the Technical Validation Group, and 20 patients

Measurements will be done on 4 muscles with the WPM-SEMG device prototype using a rigid electrode matrix. For each muscle, the participant will execute some spontaneous motor activities and measurements will be taken on the muscle under tension (low, medium, and high) for a total of 12 measurements. Measurements will be repeated two times after a pause for a total of 24 acquisitions. For the group with myopathies an additional fifth muscle, not foreseen by the protocol, can be done if considered the clinical most affected muscle followingthe neurological examination.

A control intervention is done on the same subjects and consists in a needle-EMG which will be applied as for routine clinical practice on the same muscles used for the WPM-SEMG device prototype. Measurements will be taken for each muscles as for the rigid matrix.

02

Conditions studied

  • Neuron Disease, Motor

Browse trials for

03

In context

Motor Neuron Disease

203 studies on the registry are indexed under Motor Neuron Disease; 61 are open to participants now.

This study's planned enrollment of 70 is above the median of 30 across 104 interventional studies indexed under Motor Neuron Disease.

Browse Motor Neuron Disease studies →

Lead sponsor

Alain Kaelin is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Eligibility criteria for healthy volunteers

  • Inclusion Criteria

    • Healthy volunteers
    • Female or male
    • 18 years or older
    • Preserved cognitive capacity
    • Ability to understand the study
    • Willingness to complete all the study assessments
    • No chronic or concomitant use of medications or treatment
    • Written
  • Exclusion Criteria

    • Skin lesions in the area below the electrode
    • Allergy to metal alloys
    • History of skin disease
    • Pregnancy
    • Lactation
    • Known causes of neuromuscular disease
    • Inability to follow the procedures of the study

Eligibility criteria for patients

  • Inclusion Criteria

    • Patients of the Neurocentro della Svizzera Italiana with diagnosis of myopathy or neuropathy that requires a needle-EMG electrophysiological testing as standard clinical management of the disease
    • Female or male
    • 18 years or older
    • Preserved cognitive capacity
    • Ability to understand the study
    • Willingness to complete all the study assessments
    • No chronic or concomitant use of medications or treatment that may influence the measure in the opinion of the investigator (muscle relaxant such as baclofen, statin, benzodiazepine).
    • Written informed consent
  • Exclusion Criteria

    • Skin lesions in the area below the electrode
    • Allergy to metal alloys
    • History of skin disease
    • Cognitive and/or psychiatric disorders
    • Pregnancy
    • Lactation
    • Neuromuscular disease other than myopathy and neuropathy
    • Inability to follow the procedures of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Muscle electrophysiological signals recording

    Recording of electrophysiological signals of muscles with a WPM-SEMG prototype

    Device: WPM-SEMG prototype

Interventions

  • DeviceWPM-SEMG prototype

    Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix

06

What researchers measure

Primary outcomes

  1. Technical and clinical assessment

    Correlation between the properties of the final electrophysiological output identified from sEMG signals acquired with the WPM-SEMG device prototype and the properties of the final electrophysiological output identified from EMG signals acquired using needle EMG. \[Time Frame: Intervention (day0)\] The following properties will be extracted: Amplitude (microVolts), phases/turns (ratio), signal frequency (Hz) and duration (seconds).

    Time frame: Intervention (day0)

Secondary outcomes

  1. Pain assessment

    Pain assessment during the measurements using the Visual Analog Scale (VAS). The VAS consists on a 0-10 scale, with two end points representing 0 ('no pain') and 10 ('worst possible pain').

    Time frame: Intervention (day0)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Apr 2026, 99 months after the start.

Of 32 interventional studies with no phase under Motor Neuron Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 77. This study's planned 99 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2018
First posted
Sep 4, 2024
StartActual
Jan 19, 2018
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06584084
Lead sponsor
Alain Kaelin
Collaborators
University of Applied Sciences and Arts of Southern Switzerland, Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Alain Kaelin (Prof., Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Sep 4, 2024
Start date
Jan 19, 2018
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Alain Kaelin, Prof.
Contact
alain.kaelin@eoc.ch
+41 (0)91 811 62 57
Manuela Maffongelli
Contact
manuela.maffongelli@supsi.ch
+41 (0)58 666 65 41

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion